CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Research organization IAVI receives US funding for Ebola vaccine development

By Reuters News

Oct 28 (Reuters) - IAVI, a biomedical research organization, said on Wednesday it was awarded $36 million under a US government contract worth up to $99 million to advance development of its single-dose vaccine candidate against the Bundibugyo strain of the Ebola virus.

The number of confirmed Ebola cases in Democratic Republic of Congo has risen above 10,000, government data showed on Tuesday, making the Bundibugyo outbreak the country's largest and deadliest.


Here are more details:

  • The US Biomedical Advanced Research and Development Authority award supports manufacturing of vaccine doses for clinical testing and outbreak response, including an early-stage trial

  • It also supports development of an updated candidate targeting the variant behind the 2026 Bundibugyo outbreak

  • There are currently no approved vaccines or specific treatments for disease caused by Bundibugyo virus

  • IAVI will partner with Hilleman Laboratories, SK bioscience, and IDT Biologika for development, manufacturing and vaccine production

  • IAVI's one-dose rVSV-based vaccine candidate has demonstrated protective efficacy in animal studies, the organization said

  • Single-dose vaccines may offer practical advantages during outbreaks by allowing rapid vaccination without the logistical requirements of a multidose regimen

  • Drugmaker Regeneron REGN.O on Monday said it had extended its agreement with the US health authority to provide additional supply of its Ebola treatment

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.